No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CERS240517P5000
- 2.55
- 0.000.00%
15min DelayTrading Mar 6 12:40 ET
0.00High0.00Low
0.00Open2.55Pre Close0 Volume1 Open Interest5.00Strike Price0.00Turnover418.66%IV-3.01%PremiumMay 17, 2024Expiry Date3.17Intrinsic Value100Multiplier9DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type-0.8741Delta0.1696Gamma0.57Leverage Ratio-0.0125Theta-0.0009Rho-0.50Eff Leverage0.0006Vega
Intraday
- 5D
- 1D
News
Cerus's Strong Q1 Growth and Promising INTERCEPT Technology Drive Buy Rating
Cerus First Quarter 2024 Earnings: EPS Misses Expectations
Cerus Is Maintained at Overweight by Cantor Fitzgerald
Cerus Is Maintained at Overweight by Cantor Fitzgerald
Cerus Price Target Raised to $4.00/Share From $3.00 by Cantor Fitzgerald
Cerus Price Target Raised to $4.00/Share From $3.00 by Cantor Fitzgerald
Express News | Cantor Fitzgerald Maintains Overweight on Cerus, Raises Price Target to $4
Cerus Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/03/2024 130.55% Cantor Fitzgerald $3 → $4 Maintains Overweight 04/12/2024 188.18% Craig-Hallum → $5 Ini
Comments
$Cerus(CERS.US$ Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life
1
$Cerus(CERS.US$ Cerus Announces Positive Results For Phase 3 Trial Of Intercept Blood System
$Cerus(CERS.US$ That gap at 2.11 almost filled!
6
Read more